In this Q&A, Randa Wahid of Indero, and Lyn Mursalo, a freelance clinical research professional, share how sponsors and CROs ...

A new drug candidate has shown impressive results in a mid-stage clinical trial for drug-resistant epilepsy, raising hopes ...

Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress (IHC), ...

The upcoming meeting of the European Association for the Study of Diabetes will feature results from clinical trials in types 1 and 2 diabetes and obesity and new clinical practice guidelines.

Stroke continues to be a leading cause of mortality and long-term disability worldwide, presenting significant challenges in prevention, acute intervention, ...

In this Q&A from the 2025 Veeva R&D and Quality Summit, Ibrahim Kamstrup-Akkaoui, vice president of data systems innovation ...

A new study evaluated real-world data on the efficacy of GLP-1s in patients with obesity and heart failure with preserved ...

Weekly mobile messages improved blood sugar, blood pressure, and heart health risk management in patients with type 2 diabetes (T2D), a study finds.

New cohorts initiated in ongoing Phase 1/2 clinical trial to evaluate inobrodib in combination with teclistamab or elranatamab for the treatment of relapsed/refractory multiple myelomaInitial safety d ...

Argenica Therapeutics (ASX:AGN) will forge ahead with its clinical program for post-stroke brain protection, after releasing ...

CellCentric maintains development and commercial rights to inobrodib and is free to expand the program in combination with other agents.